Roche. Q Sales. April 14, 2011 Basel

Transcription

1

2 Roche Q Sales April 14, 2011 Basel 2

3 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as believes, expects, anticipates, projects, intends, should, seeks, estimates, future or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website All mentioned trademarks are legally protected 3

4 Group Severin Schwan Chief Executive Officer 4

5 Q1 2011: Highlights Sales Group and Pharma: low-single digit sales growth (+2% and +1% ) 1,2 Diagnostics: above market sales growth (+6% 1 ) Significant negative currency impact (-9%p) 7 positive studies in Q1, of which 6 pivotal Vemurafenib (BRAF inh.) in melanoma (BRIM3) Vismodegib (Hedgehog inh.) in basal cell carcinoma (pivotal ph II) Lucentis in DME (RIDE & RISE) Avastin in relapsed ovarian cancer (OCEANS) Tarceva in EGFR-mutated NSCLC (EURTAC) T-DM1 in 1 st line HER2-positive mbc (phase II) Operational Excellence on track to deliver announced savings 1 local currency, 2 excluding Tamiflu 5

6 Q1 2011: Group sales Supporting full-year guidance, strong currency impact change in % Excluding CHF m CHF m CHF local Tamiflu 1 Pharmaceuticals Division 9,727 8, Diagnostics Division 2,518 2, Roche Group 12,245 11, local currency 6

7 Confirming full year Pharma sales guidance of low-single digit growth 1 Q1 impact on Pharma sales growth Outlook on sales growth impact for the rest of 2011 US Healthcare Reform -0.6 %p To level out in H EU austerity measures -1.0 %p To level out in H Japan price cuts -0.7 %p To level out as of Q ODAC rec. on Avastin mbc -1.3 %p To level out as of Q local currency, excluding Tamiflu 7

8 Japan earthquake Limited impact on Roche expected Chugai Roche Diagnostics Utsunomiya plant: Bioreactors not affected, continuous energy supply currently discussed with authorities FDA approved new filling facility as planned, QC function resumed Actemra supply secured into October Chugai business expected to fully normalise by September Roche Diagnostics Japan not operationally impacted Partner Hitachi in process of resuming production of analytical instruments No disruption in the supply of spare parts, consumables or reagents Financial impact: no change to FY 2011 guidance 8

9 Key clinical trials since October positive studies in 6 months Compound Indication Study MetMAb 2 nd /3 rd line NSCLC Randomised Phase II, ESMO 2010 Avastin front line Ovarian Cancer ICON7 Phase III, ESMO 2010 Ocrelizumab RR Multiple Sclerosis Randomised Phase II, ECTRIMS 2010 Mericitabine (RG7128) Hepatitis C PROPEL randomised Phase IIb, interim data AASLD 2010 Vemurafenib (BRAF inh) Metastatic Melanoma BRIM2 Phase II, Melanoma Research Congress 2010 GA101 Non-Hodgkin's Lymphoma Randomised Phase II, ASH 2010 Glycine Reuptake inh. (GlyT-1) Schizophrenia Randomised Phase II, ACNP 2010 Pertuzumab Neoadjuvant HER2+ Breast Cancer NEOSPHERE randomised Phase II, SABCS 2010 Lebrikizumab Asthma Randomised Phase II, data in house Dalcetrapib CV risk reduction Dal-VESSEL, Dal-PLAQUE safety data in house T-DM1 1 st line HER2-positive breast cancer Randomised Phase II, Apr 2011 Vemurafenib (BRAF inh) Metastatic Melanoma BRIM3 Phase III interim analysis, Jan 2011 Tarceva Advanced NSCLC EURTAC Phase III interim analysis, Jan 2011 Avastin Relapsed Ovarian Cancer OCEANS Phase III, Feb 2011 Lucentis Diabetic macular edema (DME) RISE and RIDE, 2 Phase III studies, Feb-Mar 2011 Vismodegib (Hedgehog inh) Basal Cell Carcinoma (mbcc) Pivotal Phase II, Mar 2011 Pivotal studies in Q

10 Excellence in Research Continuing scientific breakthroughs 2010: 18 scientific publications in the 3 most prestigious journals: Nature, Science and Cell 2011: the trend continues, with ~100 publications, of which one in Cell and one in Nature IR-Updates on our major scientific publications 3-4 times a year 10

11 Confirming outlook for 2011 Sales growth (in LC) Genentech synergies Operational Excellence savings Core EPS growth target (in LC) Group & Pharma (excl. Tamiflu): low single-digit Diagnostics: significantly above market : CHF 1.0 bn* 2011 : CHF 1.8 bn : CHF 2.4 bn High single-digit Debt Aim to return to net cash position by 2015 Dividend outlook Grow dividend in-line with Core EPS growth Barring unforeseen events; LC=Local Currency; * vs. 2010: CHF 0.8 bn 11

12 Pharmaceuticals Division Pascal Soriot COO Roche Pharmaceuticals 12

13 Q1 2011: Pharma sales in line with guidance change in % Excluding CHF m CHF m CHF local Tamiflu 1 Pharmaceuticals Division 9,727 8, United States 3,647 3, Western Europe 2,597 2, Japan International 2,495 2, Quarterly growth rates % in LC vs. prior year Q1 Q2 Q3 Q4 Q1 Pharmaceuticals Division excl. Tamiflu local currency 13

14 Q1 2011: Pharma sales stable International region offsetting Western European austerity measures United States 38% Pharma sales, +2% 1 High base: strong Q Lower sales of Avastin in mbc HCV patients warehoused Western Europe 26% Pharma sales, -4% 1 Austerity measures NeoRecormon, CellCept erosion due to biosimilars and generics Lower sales of Avastin in mbc Japan 10% Pharma sales, +1% 1 Biennial price cuts effective April 2010 Strong volume growth International 26% Pharma sales, +6% 1 High base: strong Q Further increasing penetration for all major products All growth in local currencies; 1 Excluding Tamiflu 14

15 Q1 2011: Pharma Lucentis, Oncology and Actemra driving growth +35% +7% +8% +111% +23% +8% +7% -15% -14% -15% -22% +30% -6% Tamiflu: -243 m; -47% Absolute amounts in CHF m at 2010 exchange rates; products with growth contribution CHF >20 m 15

16 Q1 2011: Solid growth of the oncology franchise Avastin continues growth in International and Japan Major brands CHF bn local growth -6% +8% +7% Continued uptake in CLL and strong use in NHL Japan and Int l: continued strong growth US & WE: mbc impacted by regulatory actions WE: Benefit from uptake in gastric cancer Japan: negative impact of price cuts in April % Strong growth in key markets: US, Japan, China +8% Growth in US, Int l region and Japan Oncology Q sales: 5.0 bn 16

17 Avastin: Impact from breast cancer indication Other indications not affected CHF bn Global sales -6% 1 Regional sales Local growth US -14% Japan +22% International +16% Western Europe -8% Avastin New Patient Shares 1 st line mcrc EU: stable (Q4 10) US: stable (Q1 11) Japan: strong growth 1 local growth 1 st line mbc EU: March 2011 EMA confirmed the benefit of Avastin in combination with paclitaxel. Further growth potential with paclitaxel. US: further downward trend from ~35% at Q4 10 to ~20% (± 5%) (Q1 11) 1 st line mnsclc EU: stable (Q4 10) US: stable (Q1 11) Japan: further uptake 17

18 Lucentis Positive results from two DME trials: RIDE & RISE Diabetic Macular Edema (DME) CHF m US quarterly sales US filing H % 1 Primary end-point* Lucentis 0.3 mg Lucentis 0.5 mg Sham (Placebo) RIDE 33.6% 45.7% 12.3% RISE 44.8% 39.2% 18.1% * proportion of patients at 24 months able to read at least 15 or more additional letters on the eye chart Target US population ~205,000 patients Lucentis vs. Avastin in AMD CATT Study Data expected shortly CATT not designed to answer fundamental safety questions on intra-vitreal use of Avastin 1 in local currency; AMD = wet age-related macular degeneration; DME = diabetic macular edema Genentech, a member of the Roche Group, retains commercial rights in the US and Novartis has exclusive commercial rights for rest of the world 18

19 Actemra/RoActemra in Rheumatoid Arthritis Growing in all regions CHF m Actemra/RoActemra quarterly sales +111% 1 Q sales: CHF 129 m Uptake remains very encouraging Further gain of patient share in all treatment lines according to label Utsunomiya plant: filling facility gained FDA approval bioreactors not affected; energy supply being addressed No impact expected on supply of Actemra to customers or patients; no impact expected on the regulatory authority submissions 1 YOY growth in local currency 19

20 Source: IMS NPA Pegasys: HCV patients awaiting new therapies HCV market historically expanded with new treatments US monthly Interferon TRx volume August 97 January % -5% -19% +28% +15% -22% -10% -7% -8% -9% % % HCV segment currently contracting in mature markets, as patients delay start of therapy in anticipation of new combination therapies Pegasys expected to become the foundation of combination therapies with new antivirals Infergen Launch ( 97) Rebetron Launch (Q4 98) PEGASYS Launch (Q4 02) PEGIntron Launch (Q4 01) Pegasys ProClick: preparations for launch of new dosage form (increases patient convenience and safety) *LTC TRx component added, increasing total market volume by +2% (from 2004 onwards) 20

21 Q1 2011: Major clinical newsflow Vemurafenib (BRAF inh.) Phase III (early analysis) 1 st line met. melanoma (BRIM 3) Vismodegib (Hedgehog inh.) Pivotal phase II Advanced basal cell carcinoma Lucentis 2 x Phase III DME (RIDE & RISE) Filing 2011 US filing planned 2011 US filing 2011 Tarceva Phase III 1 st line EGFR-mutated mnsclc (EURTAC) Avastin Phase III Relapsed ovarian cancer (OCEANS) T-DM1 Phase II T-DM1 vs. Herceptin 1 st line HER2+ mbc Filing 2011 Filing 2011 Ph III EMILIA 2 nd line filing 2012 Ph III MARIANNE 1 st line filing

22 ASCO 2011: Key submissions Personalised Healthcare becoming reality Vemurafenib (BRAF inh.) BRIM 3; 1 st line met. melanoma Tarceva EURTAC; EGFR-mutated 1 st line NSCLC MetMAb 2 nd /3 rd line NSCLC; final PFS and OS data Patient selection crucial for the success of the trials Avastin OCEANS; relapsed ovarian cancer 22

23 2011: Major clinical news for late-stage NMEs 7 Phase III and 10 Phase II studies Phase II Phase III Compound Indication Study BRAF inh 1st line met melanoma BRIM3 Lucentis Diabetic macular edema RIDE RISE Avastin Relapsed ovarian cancer OCEANS Pertuzumab + Herceptin 1st line HER2+ mbc CLEOPATRA Herceptin Early HER2+BC sc HANNAH Actemra Early RA Head-to-Head against Humira 1 Hedgehog Pathway Inh. Advanced BCC Pivotal study T-DM1 1st line HER2+ mbc PFS data GA101 Relapsed indolent NHL Head-to-Head against MabThera/Rituxan MetMab NSCLC 2nd / 3rd line Final data Lebrikizumab Asthma MILLY; MOLLY Mericitabine Hepatitis C PROPEL final data; JUMP-C Dalcetrapib Atheroclerosis CV risk red. dal-vessel; dal-plaque 1 Read-out likely early

24 Diagnostics Division Daniel O Day COO Roche Diagnostics 24

25 Q1 2011: Diagnostics Division sales Above market growth Q Q CHF local CHF m CHF m growth growth Professional Diagnostics % 10% Diabetes Care % 1% Molecular Diagnostics % 3% Applied Science % -3% Tissue Diagnostics % 18% Diagnostics Division 2,518 2,408-4% 6% 25

26 Diagnostics Division sales Q Growth driven by Asia-Pacific and EMEA CHF 2,408 m local sales growth North America 25% Latin America 6% Diagnostics Division North America 6% 4% Asia Pacific 12% EMEA* 3% Japan 5% Latin America 16% EMEA 1 52% Asia Pacific 16% Japan 9% 1 Europe, Middle East and Africa 26

27 Market leadership drives sales Double-digit growth in Professional and Tissue Diagnostics CHF bn Q vs. Q local growth +10% CE-mark for cobas c 702 module plus new high-value assays HBsAg quantification (HBV) & HE4 (ovarian cancer) +1% Continued strong uptake of new bg monitoring products; US sales impacted by a challenging market environment +3% -3% +18% FDA approval for duplex test for parvovirus B19 and HAV for blood screening; CE-mark for CMV test; first publication of ATHENA HPV trial results (Am.J.Clin.Path.) Negative impact by one-time orders in Q1 10 related to H1N1 testing, particularly APAC; strong growth in custom biotech sales Strong growth driven by IHC reagent sales; launch of next generation digital tissue imaging Virtuoso software EMEA = Europe, Middle East and Africa, APAC = Asia Pacific 27

28 cobas 8000 modular analyzer series Constantly improving lab efficiency & productivity Clin. Chem. modules Immunoassay module SINGLE PLATFORM Consolidated clinical chemistry and immunoassay testing c 701 2,000 tests/hr c tests/hr e tests/hr c Reagent Manager allows continuity of the work process + Module Sample Buffer optimises sample routing = NEW c 702 FASTER TURNAROUND TIMES Seamless workflow c 702 module launch EMEA Q1 11 Improving productivity even further Targeting high volume labs US Q

29 Acquisition of PVT GmbH/ PVT Lab Systems Addition of pre- and post-analytical automation to complement Roche s product offering Roche Blood Sample Pre-analytical tasks centrifugation, decapping, aliquoting Prepared samples in racks cobas analyzer Clin. Chem. and immunoassay testing sorting & archiving Post-analytical tasks Samples stored for back-up Test Results Saves labour, decreases errors Enables connectivity to other lab instrumentation Increases lab productivity Patient records 29

30 Expanding personalised healthcare menu Measuring HBsAg levels to tailor Pegasys HBV treatment % HBV pts serocoverted 6 months post-treatment HBsAg positive patients treated with Pegasys % 0 Low (<1500) 42% Medium ( ,000) 0% High (>20,000) HBsAg levels at week 12 (IU/mL) HBsAg quant measures the amount of circulating Hepatitis B surface antigen Low HBsAg levels at 12 weeks of treatment are significantly associated with higher rates of HBeAg seroconversion post-treatment Dia & Pharma collaboration (SOAR initiative) establishes synergy, clinical value of test and benefit of tailored Pegasys treatment APAC leading example of increased value creation driving Pegasys sales and increased HBsAg monitoring Gane et al., 2011, J Hepatol;5 suppl 1:S31 (abstract 69); EASL

31 BioImagene acquisition fully integrated Launch of new Virtuoso digital image management software Comprehensive Digital Pathology Solution for labs Enables image management, including archiving and retrieval of scanned slides Allows pathologists to share slides, perform images analysis and generate comprehensive reports Includes companion algorithms which quantify staining results based on colour and morphology, increasing accuracy and reproducibility of pathologist diagnoses US launch in Q1, other markets to follow 31

32 On track to deliver targets for 2011 Q Drive above-market growth Deliver key product launches Drive Personalised Healthcare with Pharma +6% LC cobas c 702 module HE4 test GS HLA primer sets HBsAg quant test Continue strong growth in emerging markets +17% E7 mkts 32

33 Group Alan Hippe Chief Financial Officer 33

34 Agenda Initial period: deepen understanding of Roche and the healthcare industry April/May roadshows: listen to the financial market 34

35 Exchange rate impact on sales growth Negative impact, particularly from USD and EUR Local sales growth Q vs. Q Local USD EUR -0.1% -3.9% -3.1% Oth Europe As-Pac Lat-Am Other Jap CHF -9.2% CHF sales growth Q vs. Q % -0.4% -0.4% -0.2% -0.1% 35

36 Q1 2011: Group sales +2% 1 in local currency Strong currency impact +1% +6% +2% -47% 0% -9% '112-1'125 Pharma Division Diagnostics Division Group Tamiflu Group Fx 2 Group incl. CHF Tamiflu 1 Excluding Tamiflu; 2 avg December 2010 to avg YTD Mar 11 fx local absolute values at avg 2010 fx 36

37 Roche Group currency sensitivities Based on full year 2010 sales Currency sensitivities Impact of 1% rise in average exchange rate versus Swiss franc Sales (mchf) US dollar 168 Euro 119 Japanese yen 48 All other currencies 117 Monthly updated currency sensitivities model available on Roche internet site (ROFIS): 37

38 Confirming outlook for 2011 Sales growth (in LC) Genentech synergies Operational Excellence savings Core EPS growth target (in LC) Group & Pharma (excl. Tamiflu): low single-digit Diagnostics: significantly above market : CHF 1.0 bn* 2011 : CHF 1.8 bn : CHF 2.4 bn High single-digit Debt Aim to return to net cash position by 2015 Dividend outlook Grow dividend in-line with Core EPS growth Barring unforeseen events; LC=Local Currency; * vs. 2010: CHF 0.8 bn 38

39 39

40 Roche Group Development Pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development Genentech research and early development Roche Group Q sales Diagnostics Foreign exchange rate information 40

41 Roche Group Pipeline today phase I (36 NMEs) phase II (18 NMEs + 8 Als) phase III (8 NMEs + 27 Als) Registration (6 Als) RG3639 RG7256 RG7112 RG7160 RG7167 RG7304 RG7321 RG7334 RG7414 RG7420 RG7421 RG7422 RG7440 RG7444 RG7450 RG7459 RG7593 RG7594 RG7596 RG7597 RG7604 RG7686 CHU CHU RG4934 RG7185 RG7413 RG7432 RG7236 RG7273 RG7685 RG1578 RG1662 RG7166 RG7412 RG7417 dulanermin cancer BRaf inh(2) BRAF mut. melanoma MDM2 ant (2) solid & hem tumors EGFR Mab solid tumors CIF/MEK inh solid tumors Raf & MEK dual inh solid tumors PI3 kinase inh solid tumors anti-plgf Mab solid tumors anti-egfl7 Mab solid tumors MEK inh solid tumors MEK inh solid tumors PI3 K/mTOR inh solid & hem tumors AKT inhibitor solid tumors FGFR3 Mab multiple myeloma - prostate cancer IAP ant (2) solid tum & lymphoma CD22 Mab ADC hem. malignancies antiangiogenic solid tumors - hematological malignancies anti-her3 Mab m. epithelial tumors - solid tumors anti-glypican Mab liver cancer ALK inhibitor NSCLC - solid tumors anti-il-17 Mab RA CRTH2 antag asthma Mab Beta7 ulcerative colitis nucleoside pol inh (9) HCV Cat S antag CV risk in CKD ABCA1 inducer dyslipidemia GIP/GLP-1 dual ago type 2 diabetes mglur2 antag (2) depression GABA-A a5 inv ago cogn. disorders triple reuptake inh depression anti-abeta Mab Alzheimer s anti-factor D Mab geographic atrophy Status as of March 31, 2011 RG1273 RG1273 RG3502 RG3616 RG3616 RG3638 RG3638 RG7159 RG7204 RG7433 CHU RG3637 RG4930 RG7415 RG7416 RG7449 RG7128 RG7227 RG4929 RG1512 RG7418 RG RG1450 RG1594 RG7090 EVO pertuzumab HER2+ EBC pertuzumab HER2+ mbc 2 nd line T-DM1 HER2+ EBC vismodegib advanced BBC vismodegib operable BCC MetMab mnsclc GA101 1 Ph3 in Japan MetMab mbc NHL & CLL vemurafenib met. melanoma 2nd/3rd l. navitoclax (ABT-263) sol & hem tum topoisomerase I inh gastric cancer lebrikizumab (anti-il13) asthma oxelumab (OX40L Mab) asthma rontalizumab (IFN alpha Mab) SLE anti-lt alpha Mab RA anti-m1 prime Mab asthma mericitabine (polymerase inh) HCV danoprevir (protease inh) HCV 11 beta HSD inh metabolic diseases P selectin Mab ACS/CVD anti-oxldl Mab sec prev CV events SGLT2 inh type 2 diabetes gantenerumab (A-beta) Alzheimer s ocrelizumab RMS mglur5 antag (2) TRD NMDA receptor antag TRD RG105 RG105 RG435 RG435 RG435 RG435 RG435 RG435 RG435 RG435 RG435 RG435 RG597 RG597 RG1273 RG1415 RG1415 RG3502 RG3502 RG7159 RG7159 RG7204 RG1569 RG1569 RG1569 RG1569 RG3648 RG1439 RG1658 RG3626 RG1594 RG1678 RG1678 RG3645 RG3645 Rituxan NHL fast infusion MabThera NHL sc formulation Avastin HER2+ BC adj Avastin BC combo Herceptin 1 st line Avastin NSCLC adj Avastin HER2-neg. BC adj Avastin triple-neg. BC adj Avastin relapsed ovarian ca Avastin high risk carcinoid Avastin glioblastoma 1 st line Avastin mcrc TML Avastin mbc 2 nd line Herceptin HER2+ BC subcut. Herceptin HER2+ adj BC (2yrs) pertuzumab HER2+ mbc 1 st line Tarceva NSCLC adj Tarceva NSCLC EGFR mut 1 st line T-DM1 HER2+ mbc 1 st l. T-DM1 HER2+ adv. mbc GA101 GA101 CLL inhl vemurafenib met. melanoma Actemra ankylosing spondylitis Actemra sc formulation RA Actemra early RA Actemra RA DMARD IR H2H Xolair chronic idiopathic urticaria aleglitazar CV risk reduction in T2D dalcetrapib atherosc. CV risk red. Activase extended time window AIS ocrelizumab PPMS GRI schizophrenia negative sympt. GRI schizophrenia subopt. control Lucentis diabetic macular edema Lucentis AMD high dose RG435* RG435* RG1415* RG105** RG1569 CHU Avastin ovarian cancer 1 st line Avastin BC combo Xeloda 1 s t line Tarceva NSCLC EGFR mut 1 st line Rituxan ANCA assoc vascul Actemra sjia EPOCH chemo induced anemia * submitted in the EU ** submitted in the US NME Additional Indication Oncology Inflammation/Immunology Virology Metabolic/Cardiovascular CNS Ophthalmology Others RG-No Roche Genentech managed CHU Chugai managed EVO Evotec RG105 MabThera is branded as Rituxan in US and Japan RG1569 Actemra is branded as RoActemra in EU 41

42 Changes to the development pipeline Since FY 2010 Update on February 4, 2011 New to Phase I New to Phase II New to Phase III New to Registration New NMEs transitioned from Ph0 RG7604 solid tumors RG7450 prostate cancer RG7596 hematological malignancies New NMEs in Ph2 (moved from Ph I following FPI) RG7418 anti-oxldl secondary prev. of CV events RG beta HSD inh. metabolic diseases RG3638 MetMab in mbc New AI in Ph3 (moved from Ph II) RG3648 Xolair chronic idiopathic urticaria Newly shown AI RG3626 Activase extended time window AIS (US) Removed from Phase I Removed from Phase II Removed from Phase III Removed from Reg. Removed by Chugai CHU serine palmitoyltranf inh in HCV Discontinuation (1NME) RG3487 Nic alpha 7 in Alzheimer s Disease (cognition) Reverted to Partner (1NME) RG3484 HPV16 in cervical neoplasia 42

43 Projected NME Submissions and their Additional Indications Projects Currently in Phase 2 and 3 anti-lt alpha Mab (RG7416) RA lebrikizumab (RG3637) asthma GA101 (RG7159) NHL anti-m1 prime Mab (RG7449) asthma MetMab (RG3638) mnsclc and mbc SGLT2 inh (RG7201) type 2 diabetes navitoclax ABT-263 (RG7433) solid & hem tumors aleglitazar (RG1439) CV risk reduction in T2D T-DM1 (RG3502) HER2+ mbc 1st line P selectin humab (RG1512) CVD GA101 (RG7159) CLL pertuzumab (RG1273) HER2+EBC Anti-oxLDL (RG7418) prevent secondary CV pertuzumab (RG1273) HER2+ mbc1st line mericitabine (RG7128) HCV vismodegib (RG3616) operable basal cell ca 11 beta HSD (RG4929) metabolic diseases vemurafenib (RG7204) met. melanoma dalcetrapib (RG1658) atherosclerosis CV risk red. danoprevir (RG7227) HCV rontalizumab (RG7415) SLE gantenerumab (RG1450) Alzheimer s disease vismodegib (RG3616) adv basal cell ca (US) T-DM1 (RG3502) HER 2+ advanced mbc glycine reuptake inhib. (RG1678) schizophrenia# ocrelizumab (RG1596) PPMS and RMS oxelumab (RG4930) asthma mglur5 antag (2) (RG7090) Txt resistant depression Post 2014 Unless stated otherwise, submissions are planned to occur in US and EU. Filing timelines in EU subject to discussion with EMA. # negative symptoms and sub-optimal control. Oncology Inflammation/Immunology Virology Metabolic/Cardiovascular CNS Ophthalmology NME 43 Status as of March 31, 2011

44 Projected additional indications submissions of existing products Projects currently in Phase 2 and 3 Avastin HER 2+ BC adj Avastin mbc 2 nd line (EU) Avastin mcrc TML Avastin triple negative BC adj Rituxan NHL faster infusion (US) Herceptin sc formulation HER2+ Avastin glioblastoma 1 st line Avastin ovarian cancer 1 st line (US) Avastin + Herceptin HER2+ mbc 1 st line Herceptin HER 2+ BC adj 2 year Avastin relapsed ovarian cancer MabThera sc formulation (EU) Xolair (US) chronic idiopathic urticaria Tarceva (US) NSCLC EGFR mutation 1 st line Actemra ankylosing spondylitis Actemra early RA Activase extended time window AIS (US) Actemra RA DMARD H2H (EU) Actemra sc formulation (US) Avastin HER 2- BC adj Lucentis diabetic macular edema (US) Actemra sc formulation (EU) Lucentis AMD high dose (US) Tarceva NSCLC adj Avastin NSCLC adj Post 2014 Unless stated otherwise, submissions are planned to occur in US and EU. Oncology Inflammation/Immunology Virology Metabolic/Cardiovascular CNS Ophthalmology 44 Status as of March 31, 2011

45 Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development Genentech research and early development Roche Group Q sales Diagnostics Foreign exchange rate information 45

46 Avastin Breast cancer development programme Patient population First-line HER2-negative Second-line HER2-negative First-line HER2-positive Phase/study Phase III RIBBON-1 Phase III AVADO Phase III RIBBON-2 Phase III AVEREL # of patients N=1,238 N=736 N=684 N=410 Design ARM A: Anthracycline or taxane plus Avastin OR Xeloda plus Avastin ARM B: Anthracycline or taxane plus placebo OR Xeloda plus placebo Avastin dose 10 mg/kg q2 weeks or 15 mg/kg q3 wks Primary endpoint Status Progression-free survival (PFS) EU - CHMP recommended against a label extension, re-examination procedure ongoing US: FDA - Received Complete Response Letter Q ARM A: Placebo plus docetaxel ARM B: 7.5 mg/kg dose of Avastin plus docetaxel ARM C: 15 mg/kg dose of Avastin plus docetaxel 15 mg/kg or 7.5 mg/kg q3 weeks ARM A: Chemotherapy (taxane, Xeloda, gemcitabine, or vinorelbine) plus Avastin ARM B: Chemotherapy plus placebo 15 mg/kg q3 weeks ARM A: Docetaxel plus Herceptin ARM B: Docetaxel plus Herceptin plus Avastin 15 mg/kg q3 weeks Progression-free survival Progression-free survival Progression-free survival EU: Docetaxel removed from label after EC decision US: Received Complete Response Letter Q ROW: Approved in 20+ countries incl. CH EU - submission gated on RIBBON-1 procedure completion FDA - Received Complete Response Letter Q FPI Q Enrolment completed Q Expect data 2011 The EMA has confirmed that Avastin in combination with paclitaxel has been convincingly shown to enable women with metastatic breast cancer to live longer without their disease getting worse (PFS). Paclitaxel is the chemotherapy most frequently used in Europe and also most frequently partnered with Avastin for the first-line treatment of metastatic breast cancer. The FDA has granted Genentech a hearing to allow the company the opportunity to present its views on why Avastin should remain FDAapproved for metastatic breast cancer. The FDA has scheduled the hearing for June 28 to 29, Currently, and until the conclusion of the proceedings with the FDA, Avastin remains approved for use in combination with paclitaxel for the first-line treatment of HER2- negative mbc in the United States. 46

47 Avastin Ovarian cancer clinical development programme Patient population Phase/study Phase III GOG-0218 Front-line metastatic ovarian cancer Phase III ICON7 Relapsed platinum-sensitive ovarian cancer Phase III OCEANS # of patients N=1,873 N=1,528 N=484 Design ARM A: Paclitaxel and carboplatin for 6 cycles plus 5 cycles of concurrent placebo followed by placebo alone for up to 22 cycles (15 months) ARM B: Paclitaxel and carboplatin for 6 cycles plus 5 cycles of concurrent Avastin followed by placebo alone for up to 22 cycles (15 months) ARM C: Paclitaxel and carboplatin for 6 cycles plus 5 cycles of concurrent Avastin followed by Avastin alone for up to 22 cycles (15 months) ARM A: Paclitaxel and carboplatin for 6 cycles ARM B: Paclitaxel and carboplatin plus concurrent Avastin for 6 cycles followed by Avastin alone for up to 18 cycles (12 months) ARM A: Carboplatin, gemcitabine, and concurrent placebo for 6 cycles, followed by placebo alone until disease progression ARM B: Carboplatin, gemcitabine, and concurrent Avastin for 6 cycles, followed by Avastin alone until disease progression. Avastin dose 15 mg/kg q3 weeks 7.5 mg/kg q3 weeks 15 mg/kg q3 weeks Primary endpoint Status Progression-free survival Progression-free survival Progression-free survival Study met its primary endpoint with prolonged administration of Avastin (ARM C) Q Data presented at ASCO 2010 EMA submission Q Expect FDA submission 2011 Study met its primary endpoint Q Data presented at ESMO 2010 ASCO = American Society of Clinical Oncology; ESMO = European Society for Medical Oncology. Study met its primary endpoint Q Data submitted for presentation at ASCO

48 Avastin Clinical development programmes in other tumor types Patient population Phase/study Metastatic colorectal cancer Phase III ML18147 TML High risk carcinoid Phase III SWOG SO518 Newly diagnosed glioblastoma Phase III AVAglio # of patients N=810 N=284* N=920 Design 1 st -line treatment with chemotherapy* plus Avastin Once patients progress, they are randomised to: ARM A: Chemotherapy* alone ARM B: Chemotherapy* + Avastin * Physician s choice ARM A: Depot octreotide plus interferon alpha ARM B: Depot octreotide plus Avastin ARM A: Concurrent radiation and temozolomide plus placebo; followed by maintenance TMZ plus placebo for 6 cycles; then placebo until disease progression ARM B: Concurrent radiation and TMZ plus Avastin; followed by maintenance TMZ plus Avastin for 6 cycles; then Avastin (15mg/kg q3 weeks) monotherapy until disease progression Avastin dose Primary endpoint 5 mg/kg q2 weeks or 7.5 mg/kg q3 weeks 15 mg/kg q3 weeks 10 mg/kg q2 weeks or 15 mg/kg q3 weeks Overall survival Progression-free survival Progression-free survival Overall survival Status FPI Q Enrolment completed Q Expect data Q FPI Q *Protocol being amended; sample size to increase FPI Q Enrolment completed Q Expect data

49 Avastin Adjuvant clinical development programme Patient population Phase/study Adjuvant lung cancer Phase III ECOG 1505 Phase III ECOG 5103 HER2-negative Adjuvant breast cancer Phase III BEATRICE Triple-negative Phase III BETH HER2-positive # of patients N=1,500 N=4,950 N=2,530 N=3,600 Design ARM A: Cisplatin plus vinorelbine, docetaxel, gemcitabine or pemetrexed ARM B: Cisplatin plus vinorelbine, docetaxel, gemcitabine or pemetrexed plus Avastin up to 12 months ARM A: Anthracycline plus cyclophosphamide (AC) followed by paclitaxel ARM B: AC plus Avastin followed by paclitaxel plus Avastin ARM C: AC plus Avastin followed by paclitaxel plus Avastin, followed by Avastin up to 12 months ARM A: Anthracycline ± taxane or taxane-based chemo alone ARM B: Anthracycline ± taxane or taxane-based chemo plus Avastin for 1 year Avastin dose 15 mg/kg q3 weeks 15 mg/kg q3 weeks Dosing equivalent to 5 mg/kg/w Primary endpoint COHORT 1: Docetaxel/ carboplatin plus Herceptin ± Avastin COHORT 2: Docetaxel plus Herceptin ± Avastin, followed by 5-Fluorouracil, Epirubicin, Cyclophosphamide For both cohorts, patients receive Herceptin ± Avastin to complete one year of targeted therapy 15 mg/kg q3 weeks Overall survival Disease-free survival Disease-free survival Disease-free survival Status FPI Q FPI Q Expect to complete enrolment Q FPI Q Enrolment completed Q FPI Q Enrolment completed Q

50 Herceptin The standard of care for HER2+ early and mbc Patient population Adjuvant HER2-positive breast cancer Early-stage HER2-positive breast cancer Phase/study Phase III HERA Phase III HANNAH # of patients N=5,102 N=595 Design Primary endpoint Status ARM A: Herceptin for 12 months ARM B: Herceptin for 24 months ARM C: Observation Disease-free survival Final 2-year versus 1-year analysis expected in 2012; event-driven ARM A: Chemotherapy* concurrent with Herceptin subcutaneous for every three weeks for the first 8 cycles ARM B: Chemotherapy* concurrent with Herceptin intravenous for every three weeks for the first 8 cycles *Chemotherapy = docetaxel then 5-FU, epirubicin, and cyclophosphamide Serum concentration Pathologic complete response FPI Q Enrolment completed Q Expect data end of

51 MabThera/Rituxan Development programmes Patient population Phase/study Front-line follicular non- Hodgkin s lymphoma Phase III Subcutaneous study Study being conducted ex-us Oncology Front-line diffuse large B-cell or follicular non-hodgkin s lymphoma Phase IIIb RATE* Faster infusion study Immunology ANCA-associated vasculitis Phase II/III RAVE* # of patients N=405 N=450 N=197 Design ARM A: Intravenous MabThera plus chemotherapy (CHOP or CVP) ARM B: Subcutaneous MabThera plus chemotherapy (CHOP or CVP) Prospective, open-label, single arm study Non-inferiority efficacy and safety study of MabThera/Rituxan and glucocorticoids versus conventional therapy (cyclophosphamide) Responders will continue on maintenance every 8 weeks over 24 months Primary endpoint Pharmacokinetics, safety and efficacy To determine the incidence of Grade 3 or 4 infusion-related toxicities resulting from faster infusion of MabThera/Rituxan Status FPI Q FPI Q Enrolment completed Q Expect data H Induction of complete remission at 6 months, defined as a BVAS/WG of 0 and off glucocorticoid therapy Data presented at ACR 2009 US sbla submission Q *In collaboration with Biogen Idec CHOP = Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone; CVP = Cyclophosphamide, Vincristine and Prednisolone. 51

52 Tarceva New approaches to treating lung cancer Patient population Phase/study # of patients Design Primary endpoint Adjuvant non-small cell lung cancer Phase III RADIANT N=974 (2:1 randomisation) Following surgical resection ± adjuvant chemotherapy: ARM A: Tarceva up to 2 years ARM B: Placebo up to 2 years Disease-free survival EGFR IHC and/or FISH-positive Status Enrolment completed Q Expect final results in 2013 First-line metastatic non-small cell lung cancer EGFR mutation-positive* Phase III EURTAC First-Line metastatic non-small cell lung cancer EGFR mutation-positive* Phase III OPTIMAL Study conducted in China N=174 N=165 ARM A: Tarceva ARM B: Chemotherapy (platinum-based doublet) Progression-free survival Study met its primary endpoint Q Expect FDA snda submission in 2011 ARM A: Tarceva ARM B: Gemcitabine and carboplatin Progression-free survival Positive data presented at ESMO 2010 *In Q we submitted an application to the EMA to extend the label for Tarceva to include patients with first-line mnsclc with EGFR activating mutations. The submission was based on published data. Data from the Phase III OPTIMAL study shared with the EMA. In collaboration with OSI Pharmaceuticals, now part of Astellas group of companies in the US. Tarceva is a trademark of OSI pharmaceuticals, LLC 52

53 Actemra/RoActemra Interleukin 6 receptor inhibitor Rheumatoid arthritis programme Patient population Early moderate-to-severe rheumatoid arthritis Rheumatoid arthritis DMARD inadequate responders Moderate-to-severe rheumatoid arthritis Moderate-to-severe rheumatoid arthritis Phase/study Phase III FUNCTION Phase III ADACTA Head-to-head study Phase III SUMMACTA Subcutaneous study Phase III BREVACTA Subcutaneous study # of patients N=1,128 N=300 N=1,200 N=600 Design ARM A: Actemra 8 mg/kg ARM B: Actemra 8 mg/kg plus MTX ARM C: Actemra 4 mg/kg plus MTX ARM D: MTX alone ARM A: Actemra ARM B: Humira Add-on to DMARD therapy Weekly dosing ARM A: Subcutaneous Actemra plus intravenous placebo ARM B: Intravenous Actemra plus subcutaneous placebo Add-on to DMARD therapy Dosing every two weeks ARM A: Subcutaneous Actemra ARM B: Subcutaneous placebo Primary endpoint DAS28 remission at 24 weeks DAS28 at 24 weeks ACR 20 at week 24 ACR 20 at week 24 Status FPI Q FPI Q Expect data early 2012 FPI Q Expect data 2012 Expect FPI Q In collaboration with Chugai MTX = Methotrexate; DMARD = Disease-Modifying Anti-Rheumatic Drugs. Humira (adalimumab) is a registered trademark of Abbott Laboratories. 53

54 Actemra/RoActemra Interleukin 6 receptor inhibitor Additional phase III programmes Patient population Systemic juvenile idiopathic arthritis (sjia) Ankylosing spondylitis NSAID failures and TNF-naive Ankylosing spondylitis TNF inadequate responders Phase/study Phase III TENDER Phase III BUILDER 1 Phase III BUILDER 2 # of patients N=108 N=502 N=250 Design Primary endpoint ARM A: Actemra 8 mg/kg and 12 mg/kg every 2 weeks for 12 weeks (dosed by body weight) ARM B: Placebo for 12 weeks Reduction in signs and symptoms plus absence of fever Status FDA and EMA submissions Q FDA and EMA granted accelerated review PART 1: ARM A: Actemra 8 mg/kg for 12 weeks ARM B: Placebo for 12 weeks PART 2: ARM C: Actemra 8 mg/kg for 24 weeks ARM D: Actemra 4 mg/kg for 24 weeks ARM E: Placebo for 24 weeks ARM A: Actemra 8 mg/kg ARM B: Actemra 4 mg/kg ARM C: Placebo ASAS20 at week 12 ASAS20 at week 12 FPI Q FPI Q In collaboration with Chugai TNF = Tumor Necrosis Factor; ASAS = Ankylosing Spondylitis Assessment Score; NSAID = Non-Steroidal Anti-Inflammatory Drugs. 54

55 Lucentis For the treatment of age-related macular degeneration and retinal vein occlusion Patient population Neovascular (wet) age-related macular degeneration Diabetic macular edema Phase/study Phase III HARBOR High dose study Phase III RIDE Phase III RISE # of patients N=1,110 N=382 N=378 Design Primary endpoint Randomised double-masked study comparing efficacy and safety of intravitreal injections of 0.5 mg and 2.0 mg Lucentis administered monthly or PRN in patients with wet AMD Mean change in best corrected visual acuity (BCVA) compared to baseline at 12 months Randomised, sham-controlled study of monthly intravitreal injections of 0.5 and 0.3 mg Lucentis for a total of 36 injections in patients with clinically significant macular edema with center involvement secondary to diabetes mellitus (Type I or Type II). Proportion of patients who gain 15 letters in BCVA score compared to baseline after 24 monthly injections (secondary endpoints include 36 month endpoint) Status FPI Q Enrolment completed Q Expect data H Study met its primary endpoint Q To be presented at the EURETINA Congress, London, May 29, 2011 Study met its primary endpoint Q Topline results presented at the 34th Annual Macula Society Meeting, Boca Raton, March 10, 2011 Genentech retains commercial rights in the United States and Novartis has exclusive commercial rights for the rest of the world. 55

56 Xolair Evaluating potential in Chronic Idiopathic Urticaria, an IgE related disease Patient population Chronic Idiopathic Urticaria Patients who remain symptomatic despite treatment* Phase/study Phase III ASTERIA I Phase III ASTERIA II Phase III GLACIAL # of patients N=300 N=300 N=320 Design Add-on therapy to H1 anti-histamines 24 week treatment period (q4-week) ARM A: Xolair 300 mg ARM B: Xolair 150 mg ARM C: Xolair 75 mg ARM D: Placebo Add-on therapy to H1 anti-histamines 12 week treatment period (q4-week) ARM A: Xolair 300 mg ARM B: Xolair 150 mg ARM C: Xolair 75 mg ARM D: Placebo Add-on therapy to H1 anti-histamines, H2 blockers, and/or LTRA 24 week treatment period (q4-week) ARM A: Xolair 300 mg ARM B: Placebo Primary endpoint Change from baseline in UAS7 weekly itch score at Week 12 Change from baseline in UAS7 weekly itch score at Week 12 Safety Status FPI Q FPI Q FPI Q In collaboration with Novartis *Refractory to H1 anti-histamines, H2 blockers, and/or leukotriene receptor antagonists (LTRAs) at the time of randomisation. 56

57 Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development Genentech research and early development Roche Group Q sales Diagnostics Foreign exchange rate information 57

58 Vemurafenib (RG7204/PLX4032) A selective novel small molecule that inhibits the mutant BRAF Patient population Previously treated metastatic melanoma BRAF mutation positive Previously untreated metastatic melanoma BRAF mutation positive Melanoma patients with brain metastases Metastatic melanoma BRAF mutation positive Patients who have progressed on vemurafenib Phase/study Phase II BRIM2 US and Australia Phase III BRIM3 Global study Phase II Phase Ib # of patients N=132 N=675 N=20 N=~50 Design Single ARM: vemurafenib ARM A: vemurafenib ARM B: dacarbazine Single ARM: vemurafenib Single ARM: vemurafenib plus MEK Inhibitor/GDC-0973 (RG7420) Primary endpoint Best overall response rate assessed by IRC using RECIST criteria Overall survival and progression-free survival Safety Safety Status Positive data presented at the International Melanoma Congress 2010 Study met both co-primary endpoints Q Data to be presented at an upcoming medical meeting Expect regulatory submission 2011 FPI Q FPI Q vemurafenib in collaboration with Plexxikon Inc. RG7420 in collaboration with Exelixis. IRC = Independent Review Committee; RECIST = Response Evaluation Criteria in Solid Tumors. 58

59 Vismodegib (RG3616/GDC-0449 ) A novel small molecule inhibitor of the hedgehog signaling pathway Patient population Advanced basal cell carcinoma Operable basal cell carcinoma Phase/study Pivotal Phase II Phase II # of patients N=104 N=49 Design Single ARM: GDC-0449 Single ARM: GDC-0449 Primary endpoint Overall response rate Status Enrolment completed Q Positive pivotal phase II results announced March 2011 COHORT 1: Complete clearance COHORT 2: Durable complete clearance FPI Q In collaboration with Curis 59

60 Pertuzumab (RG1273) First in a new class of HER dimerization inhibitors Patient population Second-line metastatic nonsmall cell lung cancer Adjuvant HER2+ breast cancer Neoadjuvant HER2- positive breast cancer Neoadjuvant HER2- positive breast cancer Second-line HER2- positive metastatic breast cancer First-line HER2- positive metastatic breast cancer Phase/study Phase II Biomarker study Phase III Phase II TRYPHAENA Phase II NeoSphere Phase II PHEREXA Phase III CLEOPATRA # of patients N=52 N=~4,000 N=225 N=417 N=450 N=808 Design Single ARM: Pertuzumab plus Tarceva ARM A: Herceptin plus chemotherapy ARM B: Herceptin, chemotherapy plus pertuzumab ARM A: FEC followed by Taxane with Herceptin and pertuzumab (H+P given concurrently) ARM B: FEC followed by Taxane with Herceptin + pertuzumab (H+P given sequentially) ARM C: TCH + pertuzumab (H+P given concurrently) ARM A: Herceptin plus docetaxel ARM B: Herceptin, docetaxel plus pertuzumab ARM C: Herceptin plus pertuzumab ARM D: Pertuzumab plus docetaxel ARM A: Xeloda plus Herceptin ARM B: Xeloda plus Herceptin plus Pertuzumab ARM A: Pertuzumab plus Herceptin and docetaxel ARM B: Placebo plus Herceptin and docetaxel Primary endpoint Day 56 FDG-PET scan assessment 3-year disease-free survival Safety Pathologic response rate Progression-free survival Progression-free survival Status FPI Q Study closed Q Expect FPI H FPI Q FPI Q Data presented at SABCS 2010 FPI Q Enrolment completed Q Expect data 2011 FDG = Fluoro-2-deoxy-D-glucose; PET = Positron Emission Tomography; FEC = Fluorouracil, Epirubicin, and Cyclophosphamide; TCH = Docetaxel, Carboplatin, Herceptin; SABCS = San Antonio Breast Cancer Symposium. 60

61 Trastuzumab emtansine (T-DM1) (RG3502) Evaluating new treatment options in HER2+ breast cancer Patient population Neoadjuvant/ Adjuvant Patients who have progressed on HER2 targeted treatment Patients who have progressed on HER2 targeted treatment Pretreated HER2 pos. metastatic breast cancer 1 Previously untreated HER2 pos. metastatic breast cancer Phase/ study Phase II Phase Ib/II Phase III BO25734 Phase III EMILIA Randomised Phase II Phase III MARIANNE # of patients N=135 N=67 N=795 N=980 N=137 N=1,092 Design Single ARM: T-DM1 administered immediately following completion of anthracycline chemotherapy Single ARM: T-DM1 plus pertuzumab ARM A: T-DM1 ARM B: physician s choice ARM A: T-DM1 ARM B: Xeloda plus lapatinib ARM A: T-DM1 ARM B: Herceptin plus docetaxel ARM A: Herceptin plus taxane ARM B: T-DM1 plus pertuzumab ARM C: T-DM1 plus placebo Primary endpoint Cardiac event rate Safety Safety and tolerability ORR and Overall survival Co-primary endpoints: Progression-free survival (PFS) Overall survival Progression-free survival by investigator Progression-free survival assessed by IRF Status FPI Q Enrollment completed Q Interim data presented at ASCO 2010 Further data presented at SABCS 2010 Expect FPI Q FPI Q Expect PFS data 2012 Expect to submit PFS data for accelerated approval in 2012 Enrolment completed Q Preliminary data presented at ESMO 2010 Positive topline PFS data April 2011 FPI Q In collaboration with ImmunoGen ASCO = American Society of Clinical Oncology; SABCS = San Antonio Breast Cancer Symposium; ESMO = European Society for Medical Oncology. 1 Patients must have received prior treatment which included both: a taxane, alone or in combination with another agent, and trastuzumab in the adjuvant, locally advanced, or metastatic setting. 61

62 GA101 (RG7159) Type II, glycoengineered anti-cd20 monoclonal antibody Phase I/II clinical trials Patient population Front-line or relapsed indolent non-hodgkin s lymphoma (NHL) Relapsed indolent non-hodgkin s lymphoma Relapsed or refractory non-hodgkin s lymphoma or chronic lymphocytic leukaemia (CLL) Phase/study Phase Ib GAUDI Phase I/II GAUSS Phase I/II GAUGUIN # of patients N=136 N=202 N=133 Design Cohort A: GA101 plus fludarabine + cyclophosphamide Cohort B: GA101 plus CHOP Cohort C: GA101 plus bendamustine Status FPI Q Expect data 2011 Phase I portion (extended treatment for 2 years): Single agent: GA101 Phase II portion (extended treatment for 2 years): ARM A: MabThera/Rituxan ARM B: GA101 Phase I portion: Initiated Q Data presented at ASH 2009 Phase II portion: FPI Q Enrolment completed Q Expect final analysis 2011 Phase I portion: Single agent: GA101 Phase II portion: Single agent: GA101 Phase I portion: Initiated Q Updated Phase I NHL and CLL data presented at ASH 2009 Phase II portion: All cohorts completed enrolment by Q Indolent NHL data presented at EHA 2010 Aggressive NHL data presented at ASH 2010 In collaboration with Biogen Idec CHOP = Cyclophosphamide, Doxorubicin, Vincristine and Prednisone; ASH = American Society of Hematology; EHA = European Hematology Association. 62

63 GA101 (RG7159) Type II, glycoengineered anti-cd20 monoclonal antibody Phase III clinical trials Patient population Phase/study Front-line chronic lymphocytic leukaemia Patients with comorbidities Phase III CLL11 Indolent non-hodgkin s lymphoma MabThera/Rituxan refractory Phase III GADOLIN Front-line indolent non-hodgkin s lymphoma Phase III BO21223 Diffuse large B-cell lymphoma (DLBCL) Phase III BO21005 # of patients N=780 N=360 N=1,400 N=1,400 Design Primary endpoint ARM A: GA101 plus chlorambucil ARM B: MabThera/Rituxan plus chlorambucil ARM C: Chlorambucil alone ARM A: GA101 plus Bendamustine ARM B: Bendamustine ARM A: GA101 plus chemotherapy followed by GA101 maintenance ARM B: MabThera/Rituxan plus chemotherpy followed by MabThera/Rituxan maintenance ARM A: GA101 plus CHOP ARM B: MabThera/Rituxan plus CHOP Progression-free survival Progression-free survival Progression-free survival Progression-free survival Status FPI Q Expect data 2013 FPI Q Expect data 2015 Expect FPI 2011 Expect FPI 2011 In collaboration with Biogen Idec CHOP = Cyclophosphamide, Doxorubicin, Vincristine and Prednisone 63

64 MetMAb (RG3638) Anti-Met monovalent antibody that inhibits HGF-mediated activation Patient population 1 st and 2 nd -line triple negative metastatic breast cancer 2 nd - and 3 rd -line metastatic non-small cell lung cancer 2 nd - and 3 rd -line metastatic non-small cell lung cancer Prospective testing of Met receptor over-expression Phase Phase II Phase II Phase III # of patients N=180 N=170 TBD Design Primary endpoint ARM A: Avastin and paclitaxel plus MetMAb ARM B: Avastin and paclitaxel plus placebo ARM C: Paclitaxel plus MetMAb ARM A: Tarceva plus MetMAb ARM B: Tarceva plus placebo ARM A: Tarceva plus MetMAb ARM B: Tarceva plus placebo Progression free survival Progression free survival Overall survival Status FPI Q Positive data presented at ESMO 2010 LIP go decision Q Expect final data 2011 Expect FPI 2011 ESMO = European Society for Medical Oncology; LIP = Lifecycle Investment Point. 64

65 Dalcetrapib (RG1658) A first-in-class CETP modulator Patient population Phase/study Patients with CHD or CHD risk equivalents (Safety Study) Phase IIb dal-vessel Endothelial function study dal-heart Programme Global Research Initiative Patients with CHD and other CHD risk factors (Safety Study) Phase IIb dal-plaque Imaging study Stable CHD patients with recent ACS Phase III dal-outcomes Mortality and morbidity study Patients with evidence of CAD Phase III dal-plaque 2* Imaging study # of patients N=476 N=130 N=15,872 N=900 Design Primary endpoint In addition to standard medication (including statins): 36 weeks treatment duration ARM A: Dalcetrapib ARM B: Placebo Change from baseline in mean blood pressure (4 weeks) Change from baseline in % flow mediated dilatation (12 weeks) Status Initiated Q Enrolment completed Q Expect data 2011 In addition to standard medication (including statins): 24 months treatment duration ARM A: Dalcetrapib ARM B: Placebo Change from baseline of MRI plaque size/burden (12 months) Change from baseline in plaque to background (blood) ratio from an index vessel by PET/CT (6 months) Initiated Q Enrolment completed Q Expect data 2011 In addition to standard medication for ACS (including statins): Minimum of 24 months treatment duration ARM A: Dalcetrapib ARM B: Placebo Time to first occurrence of any component of the composite cardiovascular event Initiated Q Enrolment completed Q Expect interim analysis 2011; event-driven In addition to standard medication (including statins): 24 months treatment duration Uses both IMT and IVUS ultrasound imaging techniques ARM A: Dalcetrapib ARM B: Placebo Assess the change from baseline in the progression of atherosclerosis using IMT and IVUS in coronary and carotid vascular beds in the same patients Initiated Q In collaboration with Japan Tobacco *Study being conducted in collaboration with the Canadian Atherosclerosis Imaging Network and Montreal Heart Institute CHD = Stable coronary heart disease; PET/CT = Positron Emission Tomography/Computed Tomography; MRI = Magnetic Resonance Imaging; ACS = Acute Coronary Syndrome; CAD = Coronary artery disease; IMT = Intima-Media Thickness; IVUS = Intravascular Ultrasound. 65

66 Aleglitazar (RG1439) A balanced PPAR co-agonist - potential to reduce cardiovascular events in type 2 diabetes patients Patient population Phase/study Type 2 diabetes Patients with moderate and mild renal impairment Phase II AleNEPHRO Renal function study ACS patients with Type 2 diabetes Phase III AleCARDIO Cardiovascular outcomes study # of patients N=300 N=6,000 Design Primary endpoint 52 week treatment duration: ARM A: Aleglitazar (150 µg) ARM B: Pioglitazone (45 mg) Relative change from baseline in glomerular filtration rate at 60 weeks At least 2.5 years treatment period and until 950 events have occurred ARM A: Aleglitazar (150 µg) on top of SOC ARM B: Placebo on top of SOC Reduction in cardiovascular mortality, nonfatal myocardial infarction and stroke (MACE) Status FPI Q FPI Q ACS = Acute Coronary Syndrome; SOC = standard of care. 66

67 Glycine reuptake inhibitor (GlyT-1, RG1678) Positive phase II (POC study) data presented at the American College of Neuropsychopharmacology, December 2010 Patient population Acute exacerbation of schizophrenia Sub-optimally controlled symptoms of schizophrenia Persistent, predominant negative symptoms of schizophrenia Phase/study Phase II Proof of concept study Phase III NIGHTLYTE Phase III MOONLYTE Phase III TWILYTE Phase III SUNLYTE Phase III DAYLYTE Phase III FLASHLYTE # of patients N=300 N=600 N=600 N=600 N=630 N=630 N=630 Design 4-week treatment period ARM A: RG1678 daily (10 mg) ARM B: RG1678 daily (30 mg) ARM C: Olanzapine ARM D: Placebo Add-on therapy to anti-psychotics 52-week treatment period ARM A: RG1678 daily (10 mg) ARM B: RG1678 daily (20 mg) ARM C: Placebo Add-on therapy to anti-psychotics 52-week treatment period ARM A: RG1678 daily (10 mg) ARM B: RG1678 daily (20 mg) ARM C: Placebo Add-on therapy to anti-psychotics 52-week treatment period ARM A: RG1678 daily (5 mg) ARM B: RG1678 daily (10 mg) ARM C: Placebo Add-on therapy to anti-psychotics 52-week treatment period ARM A: RG1678 (10 mg) ARM B: RG1678 (20 mg) ARM C: Placebo Add-on therapy to anti-psychotics 52-week treatment period ARM A: RG1678 (5 mg) ARM B: RG1678 (10 mg) ARM C: Placebo Add-on therapy to anti-psychotics 52-week treatment period ARM A: RG1678 (10 mg) ARM B: RG1678 (20 mg) ARM C: Placebo Primary endpoint PANSS total symptom factor at week 12 PANSS positive symptom factor at week 12 PANSS positive symptom factor at week 12 PANSS positive symptom factor at week 12 PANSS negative symptom factor at week 24 PANSS negative symptom factor at week 24 PANSS negative symptom factor at week 24 Status FPI Q FPI Q FPI Q FPI Q FPI Q FPI Q FPI Q PANSS = Positive and Negative Syndrome Scale 67

68 Ocrelizumab (RG1594) 2nd generation anti-cd20 monoclonal antibody Positive phase IIb (dose-finding study) 24-week data presented at European Committee for Treatment and Research in Multiple Sclerosis, October Patient population Relapsing multiple sclerosis (RMS) Primary progressive multiple sclerosis (PPMS) Phase/study Phase III OPERA I Phase III OPERA II Phase III ORATORIO # of patients N=800 N=800 N=630 Design 96-week treatment period: ARM A: Ocrelizumab 2x 300 mg IV every 24 weeks ARM B: Rebif (interferon β-1a) 96-week treatment period: ARM A: Ocrelizumab 2x 300 mg IV every 24 weeks ARM B: Rebif (interferon β-1a) 120-week treatment period: ARM A: Ocrelizumab 2x 300 mg IV every 24 weeks ARM B: Placebo Primary endpoint Annualized relapse rate at 96 weeks versus Rebif Annualized relapse rate at 96 weeks versus Rebif Sustained disability progression versus placebo by Expanded Disability Status Scale (EDSS) Status Expect FPI Q Expect FPI Q FPI Q Rebif is a registered trademarks of EMD Serono, Inc. 68

69 Lebrikizumab (RG3637) development programme A humanized monoclonal antibody designed to bind specifically to IL-13 Moderate-to-severe adult asthma Patient population Phase/study Adult patients who are inadequately controlled on inhaled corticosteroids Phase II MILLY Proof of concept study Adult patients who are not taking inhaled corticosteroids Phase II MOLLY Dose-ranging study # of patients N=218 N=212 Design ARM A: Lebrikizumab ARM B: Placebo ARM A: Lebrikizumab (low dose) ARM B: Lebrikizumab (medium dose) ARM C: Lebrikizumab (high dose) ARM D: Placebo Status Enrolment completed Q LIP go decision Q Data to be presented at an upcoming medical meeting in 2011 FPI Q Enrolment completed Q Data to be presented at an upcoming medical meeting in 2011 LIP = Lifecycle Investment Point 69

70 Mericitabine (RG7128) Nucleoside polymerase inhibitor Patient population Treatment-naive and failure chronic hepatitis C Genotype 1 and 4 Treatment-naive and failure chronic hepatitis C Genotype 1 and 4 Chronic hepatitis C Genotype 2 and 3 Phase/study Phase IIb PROPEL Phase IIb JUMP-C Longer duration study Phase IIb # of patients N=408 N= 168 TBD Design ARM A: RG7128 (500 mg BID) + Pegasys and Copegus for 12 weeks, followed by Pegasys and Copegus for 12 weeks* ARM B: RG7128 (1000 mg BID) + Pegasys and Copegus for 8 weeks, followed by Pegasys and Copegus for 16 weeks* ARM C: RG7128 (1000 mg BID) + Pegasys and Copegus for 12 weeks, followed by Pegasys and Copegus for 12 weeks* *Patients who have not achieved rapid viral (RVR) response will receive Pegasys and Copegus for a further 24 weeks. ARM D: RG7128 (1000 mg BID) + Pegasys and Copegus for 12 weeks, followed by Pegasys and Copegus for 36 weeks ARM E: Pegasys and Copegus for 48 weeks ARM F (non-responder to ARM E): RG7128 (1000 mg BID) + Pegasys and Copegus for 24 weeks, followed by Pegasys and Copegus for 24 weeks ARM A: RG7128 (1000 mg BID) + Pegasys and Copegus for 24 weeks* *Patients achieving RVR at week 4, sustained through week 22, will stop all treatment at week 24; non-rvr patients will continue treatment with Pegasys and Copegus for another 24 weeks up to week 48. ARM B: Pegasys and Copegus for 48 weeks ARM C (non-responders to ARM B): RG7128 (1000 mg BID) + Pegasys and Copegus for 24 weeks, followed by Pegasys and Copegus for 24 weeks RG7128 in combination with Pegasys and Copegus Primary endpoint Sustained virological response (SVR) Sustained virological response (SVR) Status Cohort 1 - FPI Q2 2009; Cohort 2 FPI Q ARM A to E enrolment completed Q FPI for ARM F Q Interim data presented at AASLD 2010 Expect final data 2011 FPI Q ARM A and B enrolment completed Q FPI ARM C Q Interim data presented at EASL Expect final data 2011 Expect to initiate in H In collaboration with Pharmasset AASLD = American Association for the Study of Liver Disease; EASL = European Association for the Study of the Liver 70

71 Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development Genentech research and early development Roche Group Q sales Diagnostics Foreign exchange rate information 71

72 Oncology development programmes Small Molecules Apoptosis MAPK signaling Molecule MDM2 antagonist (RG7112) BRAF inhibitor(2) (RG7256) MEK inhibitor (CIF, RG7167) Raf/MEK inhibitor (CK127, RG7304) Patient population Advanced solid tumors Hematologic neoplasms (Leukaemia) BRAF mutated solid tumors Solid tumors Solid tumors Phase Phase I Phase I Phase I Phase I Phase I Status Initiated January 2008 Expect to initiate Phase Ib studies in 2012 Initiated June 2008 Preliminary results presented at ASH 2010 Expect to initiate Phase Ib studies in 2012 FPI Q Initiated April 2008 Go decision Q Phase I study continuing, further 80 patients to be enrolled Initiated October 2008 Phase I study stopped enrolment in Q Collaborator Plexxikon Chugai Chugai 72

73 Oncology development programmes Monoclonal Antibodies Molecule Growth factor signaling Anti-glypican-3 MAb (GC33, RG7686) Angiogenic signaling Anti-PlGF MAb (RG7334) Patient population Metastatic liver cancer (hepatocellular carcinoma) Glioblastoma multiforme Hepatocellular carcinoma (HCC) Phase Phase I Phase Ib/II Phase Ib # of patients N= N=60-70 Design Dose escalation study Part 1 - Dose escalation portion RG7334 in combination with Avastin Part 1 - Dose escalation portion RG7334 in combination with sorafenib Primary endpoint Part 2 ARM A: Avastin ARM B: Avastin plus RG7334 Safety Part 1 - Establish dosing for Part 2 Part 2 - PFS at 6 months Part 2 ARM A: Sorafenib ARM B: Sorafenib plus RG7334 Part 1 - Establish dosing for Part 2 Part 2 - Safety, PK, PD Status Study ongoing Expect FPI Q FPI Q Collaborator Chugai ThromboGenics & BioInvent 73

74 GA201 (RG7160) Glycoengineered anti-egfr monoclonal antibody Patient population Head and neck squamous cell carcinoma 1 st -line metastatic non-small cell lung cancer 2 nd -line metastatic colorectal cancer Phase Mechanism of action study Phase Ib/II Phase II # of patients N=45 N=160 N=160 Design ARM A: GA201 ARM B: Cetuximab Treated until disease progression: Squamous ARM A: GA201 plus cisplatin and gemcitabine ARM B: Cisplatin and gemcitabine Non-Squamous ARM A: GA201 plus cisplatin and pemetrexed ARM B: Cisplatin and pemetrexed KRAS Wild Type ARM A: GA201 plus FOLFIRI ARM B: Cetuximab plus FOLFIRI KRAS Mutant ARM A: GA201 plus FOLFIRI ARM B: FOLFIRI alone Primary endpoint Pharmacodynamic Part 1 Safety Part 2 PFS PFS Status FPI Q FPI Q Expect FPI Q

75 Inflammation development programmes Molecule CRTH2 antagonist (RG7185) humab IL-17 (RG4934) humab OX40L (RG4930) Patient population Asthma Psoriatic arthritis Asthma Phase Phase I Phase I Phase II EquinOX # of patients N=80 N= up to 21 N=28 Design Single and multiple doses Multiple doses ARM A: RG4930 ARM B: Placebo Status Collaborator Enrolment initiated in healthy volunteers in Q Enrolling Enrolment completed Q Genmab DMARD = Disease-Modifying Anti-Rheumatic Drugs; NSAID = Non-Steroidal Anti-Inflammatory Drugs. 75

76 Virology development programmes Molecule Nucleoside polymerase inh (9) (RG7432) DAA Combo Program (RG7320) Patient population Phase Chronic hepatitis C Phase I Treatment-naïve Chronic hepatitis C Genotype 1 Phase IIb INFORM-SVR Direct Acting Antiviral (DAA) study # of patients N=60 N=160 Design Dose-escalation study ARM A: Ritonavir (100 mg bid) plus danoprevir (100 mg bid) plus RG7128 (1000 mg bid) with Copegus ARM B: Ritonavir (100 mg bid) plus danoprevir (100 mg bid) plus RG7128 (1000 mg bid) If patients are virus negative at weeks 2 and 10, patients will be re-randomized to stop therapy at week 12 or receive another 12 weeks of treatment for a total of 24 weeks. Primary endpoint Status FPI Q FPI Q Collaborator Sustained virological response 24 weeks after the end of study treatment Pharmasset 76

77 Danoprevir (RG7227) HCV protease inhibitor Patient population Treatment-naïve chronic hepatitis C Genotype 1 Treatment-naïve chronic hepatitis C Genotype 1 and 4 Phase/study Phase Ib Phase IIb ATLAS Triple combo study Phase IIb DAUPHINE # of patients N=60 N=232 N=405 Design Danoprevir boosted by low dose ritonavir in combination with Pegasys and Copegus for 15 days Cohort 1: Danoprevir 100 mg twice-daily Cohort 2: Danoprevir 200 mg once-daily Cohort 3: Danoprevir 200 mg twice-daily Cohort 4 (amendment): Danoprevir 100 mg twice-daily for 12 weeks* Part 1: ARM A: Danoprevir 300 mg q8h + Pegasys and Copegus for 12 weeks ARM B: Danoprevir 600 mg q12h + Pegasys and Copegus for 12 weeks ARM C: Danoprevir 900 mg q12h + Pegasys and Copegus for 12 weeks (ARM discontinued Q4 2009) ARM D: Placebo + Pegasys and Copegus for 48 weeks Danoprevir boosted by low dose ritonavir in combination with Pegasys and Copegus ARM A: Ritonavir + Pegasys + Copegus + Danoprevir 200 mg for 24 weeks ARM B: Ritonavir + Pegasys + Copegus + Danoprevir 100 mg for 24 weeks ARM C: Ritonavir + Pegasys + Copegus + Danoprevir 50 mg for 24 weeks ARM D: Ritonavir + Pegasys + Copegus + Danoprevir 100 mg* ARM E: Pegasys and Copegus *If patients are virus negative at week 2 and 10, patients will stop therapy at week 12. Primary endpoint Protocol amended to evaluate 12 weeks of treatment Sustained virological response 24 weeks after the end of study treatment Sustained virological response 24 weeks after the end of study treatment Status FPI Q Top-line results announced Q for first 3 cohorts; results for first 3 cohorts presented at EASL 2010 Results of cohort 4 week 12 presented at EASL 2011 FPI Q In Q4 2009, the DMC recommend that the danoprevir 900 mg cohort be discontinued; study was amended Top-line results announced Q for Part 1 4-week rapid virologic response and 12-week early virologic response rates FPI Q *patients previously treated with Pegasys/RBV with less than a 2-log drop on treatments EASL = European Association for the Study of the Liver 77

78 Metabolic development programmes Molecule 11 Beta HSD inhibitor (RG4929) ABCA1 inducer (RG7273) CatS antagonist (RG7236) P-selectin humab (RG1512) GLP-1/GIP dual agonist (MAR701, RG7685) SGLT2 inhibitor (RG7201) Patient population Metabolic disease Dyslipidemia Cardiovascular Disease Prevention of saphenous vein graft disease Patients undergoing coronary artery bypass graft (CABG) surgery Acute Coronary Syndrome (ACS) Patients undergoing Percutaneous Coronary Intervention (PCI) Type 2 diabetes Type 2 diabetes Phase/study Phase II Proof of mechanism study Phase I Phase I Phase II N=384 Phase II N=516 Phase I Phase II Design 12-week treatment ARM A: RG4929 (200 mg) ARM B: Placebo Single ascending dose study 32-week treatment period ARM A: RG1512 (20 mg/kg) ARM B: Placebo ARM A: RG1512 (5 mg/kg) ARM B: RG1512 (20 mg/kg) ARM C: Placebo Multiple ascending dose study Status FPI Q FPI Q FPI Q FPI Q Expect FPI Q Collaborator Genmab Expect FPI Q Marcadia Biotech, Inc. acquisition «Go/no go» decision pending Chugai 78

79 CNS (Neuroscience) development programmes Molecule GABRA5 negative allosteric modulator (NAM) (RG1662) Gantenerumab (Anti-Αβ, RG1450) NMDA antagonist/ EVT 101 Triple reuptake inhibitor (RG7166) Patient population Down Syndrome Prodromal Alzheimer s Disease Treatment-resistant depression Depression Phase Phase I Phase I Phase II Phase II Proof of concept Phase I # of patients N=90 N=32 N=360 N=100 Design Primary endpoint Single ascending dose study/pet Food effect, Brain Receptor Occupancy, Safety Status FPI Q Enrolment completed Multiple ascending dose study Safety 104-week subcutaneous treatment period ARM A: Gantenerumab (225 mg) ARM B Gantenerumab (105 mg) ARM C: Placebo Change in Clinical Dementia Rating scale Sum of Boxes (CDR- SOB) at 2 years ARM A: Placebo ARM B: EVT 101 Montgomery-Åsberg Depression Rating Scale (MADRS) score at 28 days Dose-escalation study Safety FPI Q FPI Q FPI Q FPI Q Collaborator MorphoSys Buy-back option from Evotec 79

80 CNS (Neuroscience) development programmes Metabotropic glutamate receptor pathway Molecule mglur2 antagonist (RG1578) mglur5 antagonist (RG7090) Patient population Depression Treatment-resistant depression Fragile X Syndrome Phase/study Phase I Phase IIa Phase IIa # of patients N=104 N=48 N=68 Design Dose-escalation study ARM A: RG7090 daily dosing (multiple dosing) ARM B: Placebo daily ARM A: RG7090 ascending doses ARM B: Placebo ascending doses ARM C: RG7090 fixed dose ARM D: Placebo fixed dose Primary endpoint Safety and tolerability Safety and tolerability Safety and tolerability Status Enrolment completed Q FPI Q Enrolment completed Q FPI Q Enrolment completed for Arm A and Arm B Q

81 Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development Genentech research and early development Roche Group Q sales Diagnostics Foreign exchange rate information 81

82 Oncology development programmes Angiogenic signaling Molecule Anti-angiogenic (RG7594) Anti-EGFL7 MAb (RG7414) Patient population Advanced solid tumors Advanced solid tumors First-line metastatic non-small cell lung cancer First-line metastatic colorectal cancer Phase Phase Ia/Ib Phase Ib Phase II Prep Phase II Prep # of patients N=~54 N=72 TBD TBD Design Dose escalation study Phase Ib portion in combination with Avastin ARM A: Anti-EGFL7 plus Avastin ARM B: Anti-EGFL7 plus Avastin and paclitaxel TBD TBD Status FPI Q FPI Q Phase II go decision Q Expect FPI H Expect FPI H

83 Oncology development programmes Antibody drug conjugate (ADC) Growth factor signaling Molecule Anti-CD22 ADC (RG7593) NME ADC (RG7450) NME ADC (RG7596) Anti-FGFR3 MAb (RG7444) Anti-HER3 EGFR DAF MAb (RG7597) Patient population Hematologic malignancies Prostate Cancer Hematologic malignancies t(4;14)-positive multiple myeloma Metastatic epithelial tumors Phase Phase I Phase I Phase I Phase I Phase I # of patients N=76 N=49 N=99 N=25 N=66 Design Dose escalation study Dose escalation study Dose escalation study Dose escalation study Dose escalation study Status FPI Q FPI Q FPI Q FPI Q FPI Q Collaborator Seattle Genetics 83

84 Oncology development programmes Small molecules PI3K signaling Molecule PI3 Kinase inhibitor (GDC-0941, RG7321) Patient population Advanced Solid Tumors Advanced Solid Tumors or Non- Hodgkin s Lymphoma 1L HER2-negative metastatic breast cancer 2L HER2-positive metastatic breast cancer 1L and 2L advanced nonsmall cell lung cancer 2L metastatic non-small cell lung cancer 2L ER+ metastatic breast cancer Phase Phase Ia Being conducted in the US Phase Ia Being conducted in the UK Phase Ib Phase Ib Phase Ib Phase Ib Phase II Prep # of patients N=100 N=55 N=45 N=70 N=30 N=30 N=340 Design Dose-escalating study Dose-escalating study Single ARM: Evaluating GDC plus paclitaxel and Avastin Patients who have progressed on Herceptin-based treatment ARM A: GDC plus T-DM1 ARM B: GDC plus Herceptin ARM A: GDC plus carboplatin/ paclitaxel (Avastin-ineligible patients) ARM B: GDC plus carboplatin/ paclitaxel plus Avastin (Avastineligible patients) Single ARM: Evaluating GDC plus Tarceva ARM A: GDC plus hormonal therapy ARM B: GDC plus hormonal therapy ARM C: Hormonal therapy Status FPI Q Additional data presented at ASCO 2010 and ESMO 2010 FPI Q Additional data presented at ASCO 2010 and ESMO 2010 Study includes multiple myeloma extension cohort FPI Q FPI Q Data presented at SABCS 2010 FPI Q FPI Q Expect FPI H

85 Oncology development programmes Small molecules (continued) PI3K signaling Molecule PI3 Kinase/mTOR dual inhibitor (GDC-0980, RG7422) PI3 Kinase inhibitor (GDC-0032, RG7604) Patient population Refractory solid tumors or non-hodgkin s lymphoma Refractory solid tumors or non-hodgkin s lymphoma Metastatic breast cancer Solid tumors Solid tumors Renal cell carcinoma Solid tumors Phase Phase Ia Phase Ia Phase Ib Phase Ib Phase Ib Prep Phase II Prep Phase I # of patients N=75 N=65 N=65 N=80 N=95 N=80 N=45 Design Dose escalation study Dose escalation study Dose escalation study ARM A: GDC plus paclitaxel ARM B: GDC-0980 plus Avastin and paclitaxel ARM C: GDC-0980 plus Herceptin and paclitaxel Dose escalation study ARM A: GDC plus carboplatin and paclitaxel ARM B: GDC-0980 plus Avastin, carboplatin and paclitaxel ARM A: GDC Xeloda ARM B: GDC plus FOLFOX and Avastin ARM A: GDC ARM B: Everolimus Dose escalation study Status FPI Q Data presented at ASCO 2010 and ESMO 2010 FPI Q Data presented at ASCO 2010 and ESMO 2010 FPI Q FPI Q Expect FPI H ASCO = American Society of Clinical Oncology; ESMO = European Society for Medical Oncology. Expect FPI H FPI Q

86 Oncology development programmes Small molecules (continued) Molecule Patient population AKT pathway MAPK signaling Apoptosis AKT Inhibitor (GDC-0068, RG7440) MEK Inhibitor (GDC-0623, RG7420) MEK Inhibitor (GDC-0973, RG7421) Solid tumors Solid tumors Solid tumors Solid tumors Phase Phase Ia Phase I Phase I Phase Ib # of patients Design Metastatic melanoma BRAF mutation positive Patients who have progressed on RG7204 Phase Ib BRIM7 IAP Antagonist(2) (GDC-0917, RG7459) Solid tumors or lymphoma Phase I N=57 N=62 N=90 N=62 N=~50 N=65 Dose escalation study Dose escalation study Dose escalation study Status FPI Q FPI Q FPI Q Genentech exercised opt-in right Q Evaluating GDC and PI3 Kinase Inhibitor (GDC-0941) FPI Q Preliminary data presented at AACR 2011 Single ARM: Vemurafenib (BRAF inhibitor) plus GDC-0973* Dose escalation study FPI Q FPI Q Collaborator Array BioPharma Exelixis *RG7204 in collaboration with Plexxikon Inc. GDC-0973 in collaboration with Exelixis. 86

87 Navitoclax (RG7433) development programme Small molecule designed to restore apoptosis by blocking the function of pro-survival Bcl-2 family proteins Phase I studies Patient population Solid tumors Relapsed or refractory CD20+ lymphoid malignancies Relapsed or refractory chronic lymphocytic leukaemia Phase Phase I/Ib M Phase Ib M Phase Ib M Phase Ib M Phase Ib M Phase Ib M # of patients N=60 N=50 N=50 N=35 N=24 N=36 Design ARM A: Navitoclax + Tarceva ARM B: Navitoclax alone Single ARM: Navitoclax+ docetaxel Single ARM: Navitoclax+ gemcitabine Single ARM: Navitoclax + paclitaxel Single ARM: Navitoclax + Rituxan Status FPI Q FPI Q FPI Q FPI Q FPI Q Data presented at ASH 2010 ARM A: Navitoclax+ fludarabine, cyclophosphamide and Rituxan (FCR) ARM B: Navitoclax + bendamustine and Rituxan (BR) FPI Q Data presented at ASH 2010 In collaboration with Abbott 87

88 Navitoclax (RG7433) development programme Small molecule designed to restore apoptosis by blocking the function of pro-survival Bcl-2 family proteins Phase II studies Patient population Relapsed or refractory lymphoid malignancies Relapsed or refractory chronic lymphocytic leukaemia Front-line chronic lymphocytic leukaemia Phase Phase I/IIa M Phase I/IIa M Phase II FRANC # of patients N=84 N=60 N=120 Design Single ARM: Navitoclax Single ARM: Navitoclax ARM A: Rituxan ARM B: Rituxan + navitoclax for a maximum of 12 weeks ARM C: Rituxan + navitoclax until progression, relapse, or unacceptable toxicity Status FPI Q Initiated Phase IIa cohort Q Updated Phase I data presented at ASH 2009 Enrolment completed Q FPI Q Initiated Phase IIa cohort Q Data presented at ASH 2010 Enrolment completed Q FPI Q In collaboration with Abbott ASH = American Society of Hematology 88

89 Dulanermin (RG3639) development programme Dual pro-apoptotic receptor agonist Patient population Metastatic colorectal cancer Phase Phase Ib Phase Ib # of patients N=62 N=23 Design Dulanermin in combination with irinotecan, cetuximab or FOLFIRI Status Initiated Q Preliminary data presented at ASCO 2009 Dulanermin in combination with FOLFOX and Avastin FPI Q In collaboration with Amgen Inc. ASCO = American Society of Clinical Oncology 89

90 Immunology development programmes Molecule Anti-LT α (RG7416) Anti-M1 prime (RG7449) rhumab-β7 (RG7413) Rontalizumab (Anti-IFN α, RG7415) Patient population Rheumatoid arthritis Asthma Ulcerative colitis Systemic lupus erythematosus Phase/stud y Phase IIa ALTARA Phase IIa SOLARIO Phase I Phase II Prep Phase II ROSE # of patients N=200 N=28 N=48 TBD N=238 Design ARM A: Anti-LT alpha plus DMARD (leflunomide or methotrexate) ARM B: Humira plus DMARD (leflunomide or methotrexate) ARM C: Placebo plus DMARD (leflunomide or methotrexate) ARM A: Anti-M1 prime ARM B: Placebo Dose escalation study TBD ARM A: Placebo Part 1 IV Part 2 - Subcutaneous ARM B: Rontalizumab Part 1 IV Part 2 Subcutaneous Primary endpoint Disease Activity Score (DAS28) at Day 85 Late airway response (LAR) at Day 86 Safety and tolerability Proportion of responders at Week 24 Status FPI Q FPI Q Enrolment completed Q Phase II go decision Q Expect FPI H FPI Q Enrolment completed Q DMARD = Disease-Modifying Anti-Rheumatic Drugs Humira (adalimumab) is a registered trademark of Abbott Laboratories. 90

91 Metabolism, neuroscience and ophthalmology development programmes Molecule Patient population Phase/study Phase II Prep ABBY Cognition study Anti-Αβ (RG7412) Alzheimer s Disease Phase II Prep BLAZE Biomarker study Anti-Factor D (RG7417) Geographic Atrophy (GA) secondary to age-related macular degeneration Phase Ib/II MAHALO Anti-oxLDL (RG7418, BI-204) Secondary prevention of cardiovascular events in patients with acute coronary syndrome Phase II Proof of activity study # of patients N=360 N=72 N=120 N=120 Design Primary endpoint ARM A: Anti-Abeta subcutaneous ARM B: Anti-Abeta IV ARM C: Placebo Change in cognition (ADAScog) from baseline to week 73 ARM A: Anti-Abeta subcutaneous ARM B: Anti-Abeta IV ARM C: Placebo Change in brain amyloid load from baseline to week 69 Part 1: Open-label Multiple dosing Part 2: Randomised ARM A: Anti-Factor D injection ARM B: Sham Injection Part 1: Safety Part 2: Growth rate of GA lesion at month 12 Status Expect FPI H Expect FPI H FPI Q FPI Q ARM A: Anti-oxLDL (single dose) and statin ARM B: Anti-oxLDL (repeating dose) and statin ARM C: Placebo and statin Change in TBR as measured by FDG-PET/CT at week 12 Collaborator AC Immune BioInvent TBR = Target-to-background ratio; FDG = Fluoro-2-deoxy-D-glucose; PET = Positron Emission Tomography; CT = CAT scan. 91

92 Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development Genentech research and early development Roche Group Q sales Diagnostics Foreign exchange rate information 92

93 Geographical sales split by divisions and Group* CHF m Q Q Change in lc % Pharmaceutical Division 9,727 8,712-2 United States 3,647 3, Western Europe 2,597 2,209-4 Japan International 2,495 2,278-3 Diagnostics Division 2,518 2, United States Western Europe 1, Japan International Group 12,245 11,120 0 United States 4,209 3, Western Europe 3,682 3,175-3 Japan 1,106 1,030-5 International 3,248 3, * Geographical sales split shown here does not represent operational organization 93

94 Local sales growth (%) Quarterly development 2010 vs vs Q1 Q2 Q3 Q4 Q1 Pharmaceuticals Division excl. Tamiflu United States excl. Tamiflu Western Europe excl. Tamiflu Japan excl. Tamiflu International excl. Tamiflu Diagnostics Division Roche Group excl. Tamiflu

95 Pharma Division sales Q (vs. 2010) Top 20 products Global US W. Europe Japan International % % % % % CHF m loc CHF m loc CHF m loc CHF m loc CHF m loc MabThera/Rituxan 1, Avastin 1, Herceptin 1, Lucentis Pegasys Xeloda Tarceva Cellcept Tamiflu Neorec./Epogin Bonviva/Boniva Xolair Valcyte/Cymevene Pulmozyme Actemra Activase/TNKase Nutropin Madopar Rocephin Mircera

96 Pharma division local sales growth 1 in % Global top 20 products Q1/10 Q2/10 Q3/10 Q4/10 Q1/11 MabThera/Rituxan Avastin Herceptin Lucentis Pegasys Xeloda Tarceva CellCept Tamiflu NeoRecormon/Epogin Bonviva/Boniva Xolair Valcyte/Cymevene Pulmozyme Actemra Activase/TNKase Nutropin Madopar Rocephin Mircera Q4/09 vs. Q4/08, Q1-Q4/10 vs. Q1-Q4/09 96

97 Pharma division local sales growth in % Top 20 products by region MabThera/Rituxan Avastin Herceptin Lucentis Pegasys Xeloda Tarceva CellCept Tamiflu NeoRecorm/Epogin Bonviva/Boniva Xolair Valcyte/Cymevene Pulmozyme Actemra * * * Activase/TNKase Nutropin Madopar Rocephin Mircera Q1-Q4/11 vs. Q1-Q4/10 * > 500% US Western Europe Japan International Q2 1 Q3 1 Q4 1 Q1 1 Q2 1 Q3 1 Q4 1 Q1 1 Q2 1 Q3 1 Q4 1 Q1 1 Q2 1 Q3 1 Q4 1 Q1 1 97

98 Q1 2011: Oncology franchise* Solid growth Oncology sales CHF bn local growth +2% +2% +15% -3% -2% US Sales driven by Rituxan, Tarceva, Xeloda, Herceptin; Avastin in mbc declining following FDA actions Western Europe Continued growth of MabThera and Herceptin, significant impact of austerity measures International Continued growth of all Oncology products Japan Growth driven by Avastin, Rituxan and Tarceva * Q sales: CHF 5.0 bn 98

99 MabThera/Rituxan: Strong growth in all regions Global sales Regional sales Local growth +7% 1 US +5% CHF bn International +15% Japan +9% Western Europe +5% YTD sales of CHF bn 1st line maintenance inhl (Q4 2010): top 5 EU penetration rate up to ~30% from ~17% at Q significant growth opportunity now indication is approved CLL: as of Q top 5 EU 1st line CLL penetration rate 62% (vs 61% in Q2 2010; 56% in Q4 2009) RA: growth due to increased use in patients with an inadequate response to one or more anti-tnfs and acceptance of 6-month repeat treatment intervals 99 1 local growth

100 Herceptin Launch of gastric cancer indication Global sales Regional sales Local growth +8% 1 Western Europe +1% CHF bn US +3% Japan -3% International +25% YTD sales of CHF bn US 2 : adjuvant use in ebc strong with high stable penetration ~90%; 1st line mbc use steady at about 85%. Western Europe (top 5 EU): penetration in ebc stable ~85%, 1st line mbc use stable in the 70-80% range. US and WE: Improvement in HER2 testing quality led to increase of eligible patient pool of about 1%. HER2 testing penetration in mgc went up to 40-60%. Japan: Sales negatively impacted by price cuts implemented in April 2010 Emerging markets: Double digit growth due to improved penetration and duration of treatment in BC. 1 local growth; 2 penetration is reported as new patient share in the US, and as total patient share in top 5 EU 100

101 Xeloda Label expansions driving growth Global sales +7% 1 Regional sales Local growth International +10% CHF bn Western Europe -4% Japan +2% US +13% YTD sales of CHF 342 m In US, stable penetration in CRC and metastatic BC Global sales benefiting from new indications, including stomach cancer in China, expanded metastatic colorectal cancer and inoperable advanced or recurrent stomach cancer in Japan 1 local growth 101

102 Tarceva Strength in International region and Japan Global sales +8% 1 Regional sales Local growth Western Europe -2% Japan +22% CHF bn International +16% US +10% YTD sales of CHF 317 m US: Q1 11 NSCLC overall penetrations remain steady EU: Market penetration in mnsclc, top 5 EU (Q4 10): 2nd line: ~40%; Pricing pressure and competitive challenges from generic chemotherapies. Japan: double-digit growth 1 local growth 102

103 Inflammation/Autoimmune/Transplantation Actemra growing in all regions IAT sales CHF bn local growth +6% +17% +8% -1% +6% Q Strong growth of Actemra and MabThera/Rituxan compensated for the further CellCept decline Actemra/RoActemra Sales: CHF 129 m (+111%) Further gain of patient share in all treatment lines according to label CellCept Sales: CHF 280 m (-14%) Patent expiry key EU countries end 2010 US prescription share ~18% (Q4 2010) 103

104 Tamiflu quarterly sales Still high base effect from H CHF m Tamiflu quarterly sales (CHF m) Retail Pandemic¹ 1 Governmental & Corporate 104

105 Roche Group Development Pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development Genentech research and early development Roche Group Q sales Diagnostics Foreign exchange rate information 105

106 2011: Diagnostics Division local sales By Region and Business Area (vs. 2010) Sales CHF m Global North Am. EMEA RoW % loc growth % loc growth % loc growth % loc growth Professional Diag. 1, Diabetes Care Molecular Diag Applied Science Tissue Diagnostics Diagnostics Division 2, ,

107 Diagnostics Division quarterly sales and local growth 1 Sales CHF m Q4 09 Q1 10 Q2 10 Q3 10 Q4 10 Q1 11 % loc % loc % loc % loc % loc % loc Professional 1,190 8% 1,170 9% 1,279 12% 1,153 9% 1,256 13% 1,165 10% Diagnostics Diabetes % 708 6% 781 5% 702 4% 768 2% 643 1% Care Molecular 301 4% 294 2% 310 4% 296 7% 289 1% 274 3% Diagnostics Applied % % 223 9% 197-2% 222-7% 198-3% Science Tissue % % % % % % Diagnostics DIA Division 2,690 10% 2,518 9% 2,732 9% 2,482 7% 2,683 6% 2,408 6% 1 versus same period of prior year 107

108 Professional Diagnostics Expands cobas 8000 analyzer series with c 702 module; launch of new high value assays CHF bn 2011 vs local growth +10% +11% +8% +15% New high-throughput clinical chemistry module cobas c 702 launched in EU 2,000 test/hr and enables uninterrupted workflow Expanded test menu with four new additions: HBsAg quant, CMV, hgh, HE-4 Good uptake of cobas b 123 POC blood gas analyzer in markets where launched Enhanced exclusive automation offering with PVT acquisition to strengthen IVD leadership position 108

109 Diabetes Care Strong uptake in emerging markets CHF bn 2011 vs local growth Q1'09 Q1 '10 Q1'11 Blood Glucose +1% Insulin Delivery -11% +2% Strong uptake of new blood glucose (bg) monitoring product generation: Accu-Chek Aviva/ Performa, Accu- Chek Active and Accu-Chek Mobile Publication of STeP study in Diabetes Care confirms value of structured bg monitoring Insulin delivery sales impacted by voluntary recall of Accu-Chek FlexLink Plus infusion sets US sales impacted by challenging market and regulatory environment 109

110 Molecular Diagnostics Sales growth led by virology testing CHF m 2011 vs local growth % Q1 '09 Q1 '10 Q1'11 Virology Blood Screening Other -2% +12% Robust demand for HBV & HCV viral load testing. Strong sales performance in US FDA approval of parvovirus B19 and HAV for blood screening CE mark for CMV test (transplant patients) First publication of ATHENA trial results in Am.J.Clin.Path. Showed importance of identifying women with HPV genotypes 16 & 18 as highest risk for developing cervical cancer Blood screening sales impacted by loss of some EU contracts, starting to be offset by wins in emerging markets 110

111 Applied Science Negatively impacted by decreased H1N1 testing CHF m Q1 '09 Q1'10 Q1'11 qpcr&nap Genomic Analysis Custom Biotech Other 2011 vs local growth -3% -10% +1% +13% -16% Negative impact in sales growth from large one-time orders for MagNA Pure and LightCycler instruments in China and EMEA in Q For H1N1 testing Strengthened genomics portfolio GS Gtype HLA primer sets for HLA genotyping 4.2M CGH array for high resolution analysis Growth in Custom Biotech business 111

112 Tissue Diagnostics Growing twice the market rate CHF m 2011 vs local growth % +28% +17% Q1 '09 Q1 '10 Q1 '11 Advanced Staining Primary Staining Other Expanding portfolio of antibodies and probes leading to strong double-digit growth Continued adoption of BenchMark ULTRA driving advanced tissue staining BioImagene acquisition fully integrated, enhances commercial opportunities US launch of next generation Virtuoso digital pathology software for review of slide images 112

113 2011: Key planned product launches Professional Diagnostics Product Description Region Time Vitamin D total Measure vitamin D2 and D3 with greater precision EU H1 HE4 Tumor marker used in risk assessment of ovarian cancer in patients with pelvic mass (with CA125) EU H1 cobas c 702 module for cobas 8000 modular analyzer series Clinical Chemistry module with throughput around 2,000 tests/hour for high-volume laboratories. Features automated reagent loading, enabling consolidation of a broader test menu. EU US Q1 Q2 cobas b 123 POC system Benchtop multi-parameter analyser for blood gas, electrolytes, CO-oximetry and metabolites. For use in critical care settings at the point of care US H2 Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors EU = European Union; US = United States 113

114 2011: Key planned product launches Diabetes Care Product Description Region Time Accu-Chek Mobile LCM Next-generation strip-free blood glucose monitoring system with an integrated lancing device, significantly smaller than current version and with enhanced functionality EU H2 Accu-Chek Combo Interactive insulin delivery system combining an insulin pump (Accu-Chek Spirit Combo) and a blood glucose meter (Accu-Chek Aviva Combo) with broad data management capabilities; the meter also functions as a pump remote control US H2 Accu-Chek Nano Sleek version for high-frequency testers offering an enhanced feature set US H2 Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factor. EU = European Union; US = United States 114

115 2011: Key planned product launches Molecular Diagnostics Product Description Region Time cobas 4800 HPV Test detects HPV 16 and HPV 18 individually and 12 other high-risk genotypes in a pooled result (cervical cancer) US H2 cobas 4800 EGFR Mutation Test for identification of mutations in the EGFR gene (nonsmall cell lung cancer) EU H2 cobas 4800 KRAS Mutation Test for identification of mutations in the KRAS gene (colon cancer) EU H2 cobas 4800 BRAF V600 Mutation Test for identification of the V600 mutation in the BRAF gene (metastatic melanoma) EU, US H2 Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors. EU = European Union; US = United States 115

116 2011: Key planned product launches Applied Science Product Description Region Time GS G Type HLA primer Sets GS FLX Titanum- XL Roche Nimblegen 4.2M CGH and 2.1M CGH/SNP arrays For HLA genotyping on the GS Junior System of GS FLX System New sequencing chemistry; enables extended read lengths on the GS FLX system Ultra-high resolution arrays for CGH validation and combined CGH/SNP validation with 4.2 million and 2.1 million features for discovery of variations in gene copy numbers and single nucleotides Global Global Global H1 H1 H2 Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors 116

117 2011: Key planned product launches Tissue Diagnostics Product Description Region Time ER/PR antibody for IHC testing HER2 Dual Colour ISH Probe for ISH testing OptiView To support the diagnosis of breast cancer on BenchMark ULTRA To support the diagnosis of breast cancer US H2 Next-generation detection system for BenchMark platforms; delivers greater specificity, sensitivity, flexible detection options and improved turn-around time US US, EU H1 H1 Planned launches may be delayed or not occur as a result of adverse regulatory decisions or other factors. EU = European Union; US = United States 117

118 Q Group sales Currency impact on growth of CHF -1.1 bn or -9%p -2% +6% 0% -9% '112-1'125 Pharma Division Diagnostics Division Group Fx 1 Group CHF avg December 2010 to avg YTD Mar 11 fx local absolute values at avg 2010 fx

119 CHF / USD Monthly averages Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 1.15 Year-To-Date averages % 2010 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 119

120 CHF / USD monthly avg 2010 average YTD Mar 2010 average full year % 0.95 average YTD Mar monthly avg 2011 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 120

121 CHF / EUR Monthly averages 2010 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec % Year-To-Date averages Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 121

122 CHF / EUR average YTD Mar % average full year average YTD Mar 2011 monthly avg monthly avg 2011 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 122

123 Average exchange rates Q1 11 Q1 10 Q1 11 vs. Q1 10 EUR USD JPY % -12% -10% -8% -6% -4% -2% 0% 123

124 Exchange rate impact on sales growth Negative impact, in particular from USD and EUR Development of average exchange rates versus prior year period CHF / EUR % CHF / USD % CHF / JPY -1.7 % Difference in CHF / local growth Sales local growth growth YTD Mar 2011 vs. YTD Mar %pt CHF growth 124

125 Exchange rate impact on sales growth Negative impact, particular from USD and EUR Local sales growth Q vs. Q Local USD EUR -0.1% -3.9% -3.1% Oth Europe As-Pac Lat-Am Other Jap CHF -9.2% CHF sales growth Q vs. Q % -0.4% -0.4% -0.2% -0.1% 125

126 We Innovate Healthcare 126